Authors
Shota Tokuno, Yumie Takeshita, Daiki Matsubara, Chiaki Nomura, Miki Okumura, Yujiro Nakano, Taro Yamashita, Masao Honda, Toshinari Takamura
Published in
Journal of pharmacological sciences. Volume 162. Issue 4. Pages 319-330. Epub Oct 15, 2026.
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors influence electrolyte balance and bone metabolism. However, their effects in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes remain unclear.
40 participants with type 2 diabetes and MASLD were randomly assigned to tofogliflozin (20 mg/day) or glimepiride (0.5-6.0 mg/day) for 48 weeks. Changes in anthropometric measures, electrolytes, and bone metabolism markers were evaluated.
Tofogliflozin significantly increased serum magnesium (2.0 ± 0.19 to 2.13 ± 0.18 mg/dL) and transiently elevated serum calcium (9.15 to a maximum of 9.60 mg/dL) and tartrate-resistant acid phosphatase 5 b (283.5 to 352.0 mU/dL). It also transiently reduced serum potassium (4.05 ± 0.31 to 3.89 ± 0.21 mEq/L) and uric acid (5.10 to a minimum of 4.55 mg/dL), accompanied by increased urinary potassium excretion and fractional uric acid excretion. Urinary magnesium and calcium excretion did not change significantly. In the tofogliflozin group, reductions in steatosis and hepatocellular ballooning scores were significantly correlated with increases in serum type I collagen cross-linked N-telopeptide.
Tofogliflozin modified electrolyte profiles and transiently influenced bone turnover markers. The observed correlations suggest a potential association between improvements in hepatic histology and changes in bone metabolism during SGLT2 inhibitor therapy.
PMID:
43020535
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0